11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity (Q58896395)

title

11-Beta-hydroxysteroid dehydrogenase type 1 (11β-HSD1) inhibitors in Type 2 diabetes mellitus and obesity (English)

0 references

0 references

1 reference

Scott P Webster

2

0 references

author name string

Katherine A Hughes

series ordinal

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

Brian R Walker

series ordinal

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

Scott P Webster

series ordinal

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

Expert Opinion on Investigational Drugs

18 May 2020

language of work or name

English

0 references

publication date

25 March 2008

0 references

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

volume

17

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

page(s)

481-496

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

issue

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

Global prevalence of diabetes: estimates for the year 2000 and projections for 2030

18 May 2020

cites work

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Overweight, obesity, and health risk

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

The relationship of body mass index to diabetes mellitus, hypertension and dyslipidaemia: comparison of data from two national surveys

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Body-Mass Index and Mortality in a Prospective Cohort of U.S. Adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Association between regional adipose tissue distribution and both type 2 diabetes and impaired glucose tolerance in elderly men and women

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

21 January 2018

The metabolic syndrome

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Banting lecture 1988. Role of insulin resistance in human disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Risks for all-cause mortality, cardiovascular disease, and diabetes associated with the metabolic syndrome: a summary of the evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Hypothalamic arousal, insulin resistance and Type 2 diabetes mellitus.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Increased urinary free cortisol: a potential intermediate phenotype of essential hypertension.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Elevated late-night salivary cortisol levels in elderly male type 2 diabetic veterans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Elevated plasma cortisol in glucose-intolerant men: differences in responses to glucose and habituation to venepuncture

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Gender differences in the associations between cortisol and insulin in healthy subjects.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Independent effects of obesity and cortisol in predicting cardiovascular risk factors in men and women.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Use of oral glucocorticoids and risk of cardiovascular and cerebrovascular disease in a population based case-control study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Taking glucocorticoids by prescription is associated with subsequent cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Glucocorticoids and cardiovascular disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Minireview: hexose-6-phosphate dehydrogenase and redox control of 11{beta}-hydroxysteroid dehydrogenase type 1 activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Purification and characterization of the corticosteroid 11 beta-dehydrogenase component of the rat liver 11 beta-hydroxysteroid dehydrogenase complex

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Does central obesity reflect "Cushing's disease of the omentum"?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11Beta-hydroxysteroid dehydrogenase inhibition improves cognitive function in healthy elderly men and type 2 diabetics

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Preventing local regeneration of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 enhances angiogenesis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 lowers intraocular pressure in patients with ocular hypertension

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11beta-Hydroxysteroid dehydrogenase expression and glucocorticoid synthesis are directed by a molecular switch during osteoblast differentiation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Foetal lung maturation in 11beta-hydroxysteroid dehydrogenase type 1 knockout mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Corticosteroid metabolism in human granulosa-lutein cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

A polygenic model of the metabolic syndrome with reduced circulating and intra-adipose glucocorticoid action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

A transgenic model of visceral obesity and the metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Leptin activation of corticosterone production in hepatocytes may contribute to the reversal of obesity and hyperglycemia in leptin-deficient ob/ob mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Tissue-specific dysregulation of cortisol metabolism in human obesity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11beta-hydroxysteroid dehydrogenase type 1 mRNA is increased in both visceral and subcutaneous adipose tissue of obese patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Regulation of 11beta-HSD genes in human adipose tissue: influence of central obesity and weight loss

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Overexpression of 11beta-hydroxysteroid dehydrogenase-1 in adipose tissue is associated with acquired obesity and features of insulin resistance: studies in young adult monozygotic twins

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Subcutaneous adipose 11 beta-hydroxysteroid dehydrogenase type 1 activity and messenger ribonucleic acid levels are associated with adiposity and insulinemia in Pima Indians and Caucasians

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Increased in vivo regeneration of cortisol in adipose tissue in human obesity and effects of the 11beta-hydroxysteroid dehydrogenase type 1 inhibitor carbenoxolone.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Polyglandular autoimmune syndromes: immunogenetics and long-term follow-up.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Body fat distribution and cortisol metabolism in healthy men: enhanced 5beta-reductase and lower cortisol/cortisone metabolite ratios in men with fatty liver

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Obesity and type 2 diabetes do not alter splanchnic cortisol production in humans

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Tissue production of cortisol by 11beta-hydroxysteroid dehydrogenase type 1 and metabolic disease.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11beta-hydroxysteroid dehydrogenase type 1 activity in lean and obese males with type 2 diabetes mellitus

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Abnormal cortisol metabolism and tissue sensitivity to cortisol in patients with glucose intolerance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Increased expression of 11beta-hydroxysteroid dehydrogenase type 1 in type 2 diabetic myotubes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11beta-hydroxysteroid dehydrogenase type 1 knockout mice show attenuated glucocorticoid-inducible responses and resist hyperglycemia on obesity or stress

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Improved lipid and lipoprotein profile, hepatic insulin sensitivity, and glucose tolerance in 11beta-hydroxysteroid dehydrogenase type 1 null mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Novel adipose tissue-mediated resistance to diet-induced visceral obesity in 11 beta-hydroxysteroid dehydrogenase type 1-deficient mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Glucocorticoids and insulin sensitivity: dissociation of insulin's metabolic and vascular actions

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Type 1 11beta -hydroxysteroid dehydrogenase mediates glucocorticoid activation and insulin release in pancreatic islets

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Antiglucocorticoid treatment of depression: double-blind ketoconazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Liver-selective glucocorticoid antagonists: a novel treatment for type 2 diabetes

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11β-Hydroxysteroid dehydrogenase type 1 inhibitors as therapeutic agents

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Is 11beta-hydroxysteroid dehydrogenase type 1 a therapeutic target? Effects of carbenoxolone in lean and obese Zucker rats

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Effects of the 11 beta-hydroxysteroid dehydrogenase inhibitor carbenoxolone on insulin sensitivity in men with type 2 diabetes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 activity in vivo limits glucocorticoid exposure to human adipose tissue and decreases lipolysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Adamantyl triazoles as selective inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11beta-HSD1 inhibition ameliorates metabolic syndrome and prevents progression of atherosclerosis in mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Discovery of 4-heteroarylbicyclo[2.2.2]octyltriazoles as potent and selective inhibitors of 11beta-HSD1: novel therapeutic agents for the treatment of metabolic syndrome

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11beta-HSD1 inhibition improves triglyceridemia through reduced liver VLDL secretion and partitions lipids toward oxidative tissues.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

2-(S)-phenethylaminothiazolones as potent, orally efficacious inhibitors of 11beta-hydroxysteriod dehydrogenase type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Structural characterization and pharmacodynamic effects of an orally active 11beta-hydroxysteroid dehydrogenase type 1 inhibitor

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

The discovery of 2-anilinothiazolones as 11beta-HSD1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Arylsulfonamidothiazoles as a new class of potential antidiabetic drugs. Discovery of potent and selective inhibitors of the 11beta-hydroxysteroid dehydrogenase type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Selective inhibition of 11beta-hydroxysteroid dehydrogenase type 1 decreases blood glucose concentrations in hyperglycaemic mice

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Selective inhibition of 11 beta-hydroxysteroid dehydrogenase type 1 improves hepatic insulin sensitivity in hyperglycemic mice strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Inhibition of 11beta-hydroxysteroid dehydrogenase type 1 reduces food intake and weight gain but maintains energy expenditure in diet-induced obese mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Benzothiazole derivatives as novel inhibitors of human 11beta-hydroxysteroid dehydrogenase type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Discovery of orally active butyrolactam 11beta-HSD1 inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

beta-Keto sulfones as inhibitors of 11beta-hydroxysteroid dehydrogenase type I and the mechanism of action.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Adamantane sulfone and sulfonamide 11-beta-HSD1 Inhibitors.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Discovery and biological evaluation of adamantyl amide 11β-HSD1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Perhydroquinolylbenzamides as novel inhibitors of 11beta-hydroxysteroid dehydrogenase type 1.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Discovery and metabolic stabilization of potent and selective 2-amino-N-(adamant-2-yl) acetamide 11beta-hydroxysteroid dehydrogenase type 1 inhibitors

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

In the search for specific inhibitors of human 11beta-hydroxysteroid-dehydrogenases (11beta-HSDs): chenodeoxycholic acid selectively inhibits 11beta-HSD-I

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Effect of chenodeoxycholic acid on 11beta-hydroxysteroid dehydrogenase in various target tissues

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Coffee inhibits the reactivation of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1: a glucocorticoid connection in the anti-diabetic action of coffee?

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

A rapid screening assay for inhibitors of 11beta-hydroxysteroid dehydrogenases (11beta-HSD): flavanone selectively inhibits 11beta-HSD1 reductase activity

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11beta-hydroxysteroid dehydrogenase type 1: a tissue-specific regulator of glucocorticoid response

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

11 Beta-hydroxysteroid dehydrogenase type 1 is induced in human monocytes upon differentiation to macrophages

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Local amplification of glucocorticoids by 11beta-hydroxysteroid dehydrogenase type 1 and its role in the inflammatory response.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Liver-selective transgene rescue of hypothalamic-pituitary-adrenal axis dysfunction in 11beta-hydroxysteroid dehydrogenase type 1-deficient mice.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Active site variability of type 1 11beta-hydroxysteroid dehydrogenase revealed by selective inhibitors and cross-species comparisons

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Discovery of adamantane ethers as inhibitors of 11beta-HSD-1: Synthesis and biological evaluation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

SDR-type human hydroxysteroid dehydrogenases involved in steroid hormone activation

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Hexose-6-phosphate dehydrogenase knock-out mice lack 11 beta-hydroxysteroid dehydrogenase type 1-mediated glucocorticoid generation.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Acute in vivo regulation of 11beta-hydroxysteroid dehydrogenase type 1 activity by insulin and intralipid infusions in humans.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Adrenal glands of mouse and rat do not synthesize androgens

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Contributions of fasting and postprandial plasma glucose increments to the overall diurnal hyperglycemia of type 2 diabetic patients: variations with increasing levels of HbA(1c).

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Long term pharmacotherapy for obesity and overweight: updated meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

Glucocorticoids and 11beta-hydroxysteroid dehydrogenase in adipose tissue

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F13543784.17.4.481

10.1517/13543784.17.4.481

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18363514%20AND%20SRC:MED&resulttype=core&format=json

18 May 2020

1 reference